en.Wedoany.com Reported - On June 1, RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to invest approximately $150 million to build a radiopharmaceutical facility in Whitestown, Indiana. The project is expected to begin construction in July 2026 and be completed by January 2028, further expanding the company's radiopharmaceutical manufacturing and supply chain footprint in the central United States.
The focus of this investment lies in the fact that radiopharmaceuticals are transitioning from early-stage research and clinical trials to an industrial phase that relies more heavily on manufacturing capabilities, isotope supply, and regionalized delivery networks. RayzeBio, a biotechnology company specializing in radiopharmaceutical therapies, has been acquired by Bristol Myers Squibb and operates as a key platform for its radiopharmaceutical business. Radiopharmaceutical therapies typically deliver radioactive payloads to tumor cells via targeting molecules, imposing higher requirements on production, quality control, radiation safety, transportation timeliness, and end-hospital delivery. Compared to conventional small-molecule drugs or antibody drugs, the half-life and regulatory constraints of radiopharmaceuticals dictate that manufacturing facilities cannot solely pursue centralized capacity; they must also establish a more refined production network based on transportation radius, cold chain and radiation compliance, drug release speed, and hospital accessibility. RayzeBio's planned new facility in Whitestown, complementing its existing radiopharmaceutical manufacturing base already operational in Indianapolis, will help further embed Indiana into the U.S. radiopharmaceutical industry chain.
Local documents from Whitestown indicate that the relevant area has been included in RayzeBio's Economic Revitalization Zone, with the project involving tax abatement reviews and public hearing procedures. Public notices show that the project site is located at Allpoints at Anson Building Lot 8B in Whitestown. The Town Council adopted a related resolution on May 13 and plans to hold a public hearing on June 10.
For Bristol Myers Squibb, the value of RayzeBio lies not only in its pipeline assets but also in its radiopharmaceutical platform and manufacturing infrastructure. When Bristol Myers Squibb announced its acquisition of RayzeBio for approximately $4.1 billion in 2023, it stated that the latter possessed a differentiated platform and candidate drug pipeline in actinium-based radiopharmaceutical therapies and was building its own production facility in Indianapolis. In 2025, RayzeBio's 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis became operational. Bristol Myers Squibb stated that the facility can support clinical orders and has the capacity to deliver tens of thousands of therapeutic doses annually at full production. If the new Whitestown facility proceeds as planned, it will add new production, support, or supply chain capabilities beyond the existing manufacturing hub, providing a foundation for subsequent clinical advancement and commercial scale-up.
Indiana is emerging as a key node in the U.S. radiopharmaceutical industry. On one hand, Indianapolis offers transportation advantages for distribution across the central United States and nationwide; on the other hand, the region is attracting a cluster of companies involved in radiopharmaceutical R&D, manufacturing, logistics, nuclide supply, and regulatory services. For radiopharmaceutical companies, the geographic location of manufacturing facilities directly impacts product delivery times after release and the range of hospitals that can be served. RayzeBio's previous Indianapolis base emphasized that therapeutic products could be delivered to patient treatment facilities within three days of release. The Whitestown project, expanding within the same region, indicates the company's aim to enhance stable supply through relatively concentrated regional manufacturing capacity while mitigating the risk of over-reliance on a single facility.
Going forward, the project will require attention to tax abatement approvals, construction progress, facility functional positioning, and regulatory licensing milestones. If the Whitestown facility is successfully completed by early 2028, RayzeBio will further strengthen Bristol Myers Squibb's U.S. manufacturing capabilities in the radiopharmaceutical sector and help drive Indiana's upgrade from a single-point manufacturing base to a radiopharmaceutical industry cluster. As major pharmaceutical companies continue to enter this field, competition in radiopharmaceuticals is shifting from candidate drug R&D to a systemic competition encompassing nuclide supply, GMP manufacturing, regional distribution, and clinical commercialization capabilities.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
